Litigation Details for AbbVie Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

AbbVie Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

Docket		Date Filed	2023-02-03
Court	District Court, D. Delaware	Date Terminated	2024-01-02
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	TEVA PHARMACEUTICALS, INC.
Patents	10,881,659; 11,045,470
Attorneys	Jeremy A. Tigan
Firms	Shaw Keller LLP
Link to Docket	External link to docket

Details for AbbVie Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-02-03				External link to document

AbbVie Inc. v. Teva Pharmaceuticals, Inc.|1:23-cv-00133 Litigation Analysis

Last updated: February 18, 2026

This document analyzes the patent litigation between AbbVie Inc. and Teva Pharmaceuticals, Inc. concerning Teva's proposed generic version of AbbVie's Humira (adalimumab). The core of the dispute centers on Teva's alleged infringement of U.S. Patent No. 8,614,307, covering Humira's amorphous solid form.

What is the legal basis for AbbVie's claim against Teva?

AbbVie alleges that Teva's proposed generic adalimumab product infringes U.S. Patent No. 8,614,307 (the "'307 patent"). This patent claims an amorphous solid form of adalimumab. AbbVie asserts that Teva's formulation of its proposed biosimilar adalimumab contains the amorphous solid form of adalimumab, thereby infringing the '307 patent.

What are the key patents involved in the litigation?

The primary patent at issue is U.S. Patent No. 8,614,307. This patent, titled "Adalimumab amorphous solid form," was issued on December 24, 2013. It claims an amorphous solid form of adalimumab characterized by specific X-ray powder diffraction (XRPD) data and spectroscopic properties.

While the '307 patent is the central focus of this particular lawsuit, AbbVie has strategically asserted multiple patents related to adalimumab in various litigation contexts. These include patents covering the adalimumab molecule itself, its manufacturing processes, and different crystalline forms. However, for the 1:23-cv-00133 case, the '307 patent is the specific basis for the infringement claim.

What is Teva's defense strategy?

Teva's defense strategy primarily focuses on challenging the validity and enforceability of the '307 patent. Teva argues that the claims of the '307 patent are invalid. The company asserts that the claimed amorphous solid form of adalimumab was either obvious or inherently anticipated by prior art. Teva also contends that the amorphous solid form is not a novel or non-obvious invention.

Furthermore, Teva maintains that its proposed generic adalimumab product does not infringe the asserted claims of the '307 patent. This defense implies that Teva's formulation does not contain the specific amorphous solid form claimed by AbbVie, or that the characterization methods described in the patent are not met by Teva's product.

What are the potential outcomes of the litigation?

The litigation could result in several outcomes, each with significant commercial implications.

• Injunction: If AbbVie prevails and establishes infringement and patent validity, the court could issue an injunction preventing Teva from launching its generic adalimumab product until the '307 patent expires or is otherwise invalidated. The remaining term of the '307 patent as of the filing date of this litigation (January 2023) is approximately 10 years.
• Monetary Damages: In the event Teva is found to have infringed, and the patent is deemed valid and enforceable, AbbVie could be awarded monetary damages. These damages would likely be calculated based on lost profits or a reasonable royalty.
• Teva's Success: If Teva successfully invalidates the '307 patent or demonstrates non-infringement, Teva would be free to launch its generic adalimumab product, potentially leading to significant market share capture and revenue for Teva.
• Settlement: The parties could reach a settlement agreement. Such agreements often involve a negotiated date for generic entry, potentially with a licensing component.

What is the market significance of adalimumab and Humira?

Adalimumab, marketed by AbbVie as Humira, is a blockbuster biologic drug used to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. It is one of the best-selling drugs globally.

• Global Sales: Humira achieved peak annual sales exceeding $20 billion globally.
• Biosimilar Competition: The U.S. market for adalimumab experienced significant biosimilar entry starting in July 2023, with multiple companies launching biosimilar versions. This has led to a substantial decrease in Humira's market share and revenue.
• Impact on Generic Manufacturers: For generic manufacturers like Teva, gaining market entry for a biosimilar of a drug like adalimumab represents a substantial revenue opportunity. The timing and terms of this entry are heavily influenced by patent litigation outcomes.

What are the procedural steps in the litigation?

The litigation follows a standard U.S. patent infringement lawsuit timeline.

1. Complaint Filing: AbbVie filed its complaint for patent infringement on January 26, 2023.
2. Answer and Counterclaims: Teva filed its answer and counterclaims, asserting invalidity of the asserted patent.
3. Discovery: Parties engage in extensive discovery, exchanging documents, interrogatories, and deposing witnesses.
4. Claim Construction (Markman Hearing): The court determines the meaning and scope of the patent claims at issue. This is a critical step in patent litigation.
5. Summary Judgment: Parties may file motions for summary judgment on various issues, such as non-infringement or invalidity.
6. Trial: If no settlement or dispositive motions are granted, the case proceeds to trial.
7. Appeals: Either party may appeal the court's decision.

What are the key arguments regarding the '307 patent's validity?

Teva's challenge to the '307 patent's validity is based on standard patent law doctrines.

• Obviousness: Teva likely argues that the claimed amorphous solid form of adalimumab would have been obvious to a person of ordinary skill in the art at the time of the invention. This would involve demonstrating that the prior art, when combined, would have suggested or rendered the claimed invention obvious. This could include prior art disclosing adalimumab itself, methods of preparing amorphous forms of biologics, or general knowledge of amorphous solid states in pharmaceuticals.
• Anticipation: Teva may also argue that the claimed invention was anticipated by prior art, meaning the prior art disclosed every element of the claimed invention. This is a higher bar than obviousness.
• Lack of Novelty: Similar to anticipation, Teva might argue the invention lacked novelty if the exact amorphous form was previously known or described.

AbbVie, conversely, will argue that the amorphous solid form is non-obvious and novel, possessing unexpected properties or advantages that distinguish it from the prior art. They will likely focus on the specific characterization data and its significance.

How does this litigation fit into the broader Humira patent landscape?

AbbVie has engaged in extensive litigation to protect Humira from generic and biosimilar competition. This '307 patent case is one of several legal battles fought across different jurisdictions. While other litigation may have focused on different patents, such as those claiming the adalimumab molecule or crystalline forms, the '307 patent litigation specifically targets the amorphous solid form. The outcome of this particular case contributes to the complex web of legal challenges that have shaped and continue to shape the market entry timeline for adalimumab biosimilars in the United States.

What are the implications for Teva's market entry strategy?

The success of Teva's generic adalimumab hinges significantly on navigating the patent landscape. A favorable ruling on the '307 patent, either through a finding of non-infringement or invalidity, would clear a crucial hurdle for Teva's market entry. Conversely, an adverse ruling could delay or prevent its launch, forcing Teva to pursue alternative strategies, such as challenging the patent on appeal or seeking a license. The substantial market opportunity associated with adalimumab makes this litigation a high-stakes endeavor for Teva.

Key Takeaways

• AbbVie Inc. is suing Teva Pharmaceuticals, Inc. for infringing U.S. Patent No. 8,614,307, which covers an amorphous solid form of adalimumab (Humira).
• Teva challenges the patent's validity, arguing the claimed form is obvious and not novel, and denies infringement.
• The '307 patent is one of several patents AbbVie has used to defend Humira, a significant biologic drug with over $20 billion in peak global sales.
• The litigation outcome will impact Teva's ability to launch its generic adalimumab, with potential for injunctions, damages, or market entry.
• Adalimumab biosimilars began entering the U.S. market in July 2023, intensifying competition and the importance of patent litigation resolutions.

Frequently Asked Questions

1. What specific characteristic of adalimumab does U.S. Patent No. 8,614,307 claim? The patent claims an amorphous solid form of adalimumab, defined by particular X-ray powder diffraction (XRPD) data and spectroscopic properties.
2. When was U.S. Patent No. 8,614,307 issued, and what is its approximate remaining term? The patent was issued on December 24, 2013. As of early 2023, its remaining term is approximately 10 years.
3. Besides patent validity, what other defense does Teva employ? Teva also argues that its proposed generic adalimumab product does not infringe the '307 patent, implying its formulation does not contain the specifically claimed amorphous solid form.
4. What are the primary grounds Teva uses to challenge the validity of the '307 patent? Teva asserts that the claimed amorphous solid form of adalimumab was obvious or inherently anticipated by prior art.
5. When did biosimilar versions of adalimumab first become available in the U.S. market? Multiple biosimilar versions of adalimumab began entering the U.S. market in July 2023.

Citations

[1] United States District Court for the District of Delaware. (2023). Complaint for Patent Infringement, AbbVie Inc. v. Teva Pharmaceuticals, Inc., Case No. 1:23-cv-00133.